Home Latest Articles
Latest Articles
  • Bingbing FAN, Xing LING, Jie HE, Wen GUO, Xia WU
    Chinese Journal of Pharmaceuticals. 2026, 57(3): 365-371.
  • Lei ZHAO, Yi LIANG
    Chinese Journal of Pharmaceuticals. 2026, 57(3): 372-375.
  • Zhixi YANG, Zizhao ZHAI, Xiao YUE, Xuejuan ZHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 145-152.

    Central nervous system(CNS) diseases have become a major global public health challenge. Intranasal administration offers a promising, non-invasive delivery route for drugs to the brain by bypassing the blood-brain barrier, avoiding the first-pass effect, achieving high bioavailability of drugs in the brain, as well as improving patient compliance and convenience. However, conventional intranasal delivery is limited by rapid mucociliary clearance and poor targeting efficiency. Nano drug delivery systems exhibit unique advantages, such as a high specific surface area, adjustable structure and modifiable surfaces, which could improve drug stability, prolong mucosal retention and enhance targeted delivery to the brain. The integration of nose-to-brain targeting strategies with nanotechnology offers a promising approach for efficient drug delivery to the CNS. This review provides a systematic overview of recent advances in nose-to-brain nano drug delivery systems, focusing on key approaches to enhance delivery efficiency. It aims to offer theoretical guidance for the rational design and clinical translation of such systems.

  • Chao LIU, Shaojuan WANG
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 153-160.

    Formulation development and quality evaluation are key factors and guarantees for pharmaceutical research and development of biopharmaceutical formulation for nasal sprays. Based on the practical project experiences and a summary of research literature, this paper mainly analyzes the technical key points in the formulation development process from the aspects of formulation design, drug delivery device and quality control. More specifically, it elaborates on the action mechanism and selection basis of bioadhesive agents, and systematically summarizes the research emphasis and control methods for the characteristics and impurities of nasal spray. By integrating the quality requirements and clinical needs of nasal sprays with the quality by design(QbD) concept, this review aims to provide practical references and insights for the standardized design of innovative formulation research and development.

  • Xiaoting GENG, Guogang ZHENG, Qian SHEN, Jinqi ZHENG, Hao RUAN
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 161-166.

    As an alternative to traditional dissolution test methods, the flow-through cell method offers many advantages over the traditional apparatus. In recent years, with the deeper studies of drug release mechanism and the updating and development of preparation technologies, the application range of the flow-through cell method has been expanding. This paper reviews the application and research progress of the flow-through cell method in drug dissolution/release studies, with a focus on its advantages in dosage forms such as tablets, capsules, suppositories, and semi-solid preparations, as well as its in vitro-in vivo correlation, to provide a reference for the further optimization of this method.

  • Naihua ZHANG, Weichen CUI, Anguo ZHU, Hao WEN, Guimin ZHANG
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 167-172.

    An improved synthetic process of ruxolitinib phosphate(1) was developed. Starting from(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) methyl pivalate(2) and 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(3), [4-[1-(1-ethoxyethyl)-1H-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate(5) was prepared via Suzuki-Miyaura coupling reaction. Compound 5 was deprotected by hydrochloric acid to afford [4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate(6). Subsequent Michael addition of 6 with 3-cyclopentylacrylonitrile(4) furnished the racemic [4-[1-(2-cyano-1-cyclopentylethyl)-1H-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate(7). Chiral resolution of 7 using D-(+)-dibenzoyl-L-tartaric acid[D-(+)-DBTA] afforded (2S, 3S)-2,3-Bis(benzoyloxy) succinate salt of (R)-[4-[1-(2-cyano-1-cyclopentylethyl)-1H-pyrazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate(8). Deprotection and hydrolysis of 8 with sodium hydroxide yielded ruxolitinib(9). Finally, the target product 1 was available from 9 by salification reaction with phosphoric acid and recrystallization. The overall yield was 27% (based on 2), with the purity of 99.89% and the chiral purity of 99.88%, and the maximum single impurity less than 0.1%. The improved process features simple operation and has been verified by pilot-scale production, which was suitable for industrial production.

  • Shuigao WU, Xiaowen NIU
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 173-179.

    Starting from 4,6-dichloro-2-propylthio-5-aminopyrimidine(2) and 2-[[(3aR, 4S, 6R, 6aS)-6-aminotetrahydro-2,2-dimethyl-4H-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol (R)-mandelate(3), the target compound ticagrelor(1) was synthesized via a four-step process including nucleophilic substitution, diazotization and cyclization, amination and deprotection. The process achieved a total yield of 80.4% (based on 2) with a final purity of 99.6%. The key intermediate, 2-[[(3aR, 4S, 6R, 6aS)-6-[[5-amino-6-chloro-2-(propylthio) pyrimidin-4-yl]amino]-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol(4), was synthesized in water using tripotassium phosphate as an acid binding agent with a yield of 93.8%. This approach avoided the use of organic solvents and organic bases, reducing costs and making the process more environmentally friendly. During the preparation of compound 1, magnesium chloride was added to the system to reduce the required amount of hydrochloric acid and consequently minimize wastewater discharge. The optimized process is simple to operate, cost-effective and environmentally friendly, making it highly suitable for industrial production.

  • Yi LIU, Jianli CHEN
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 180-183.

    p-Hydroxybenzaldehyde(1) is a crucial pharmaceutical intermediate widely used in drugs such as esmolol hydrochloride, trimethoprim, and amoxicillin. Industrial production of 1 typically employs oxidation of p-cresol(2) in batch, which suffers from safety risks, inefficient mass/heat transfer, and low productivity. This study implemented a continuous-flow tubular reactor. The optimized conditions were determined as follows: cobalt chloride and azoisobutyronitrile as catalysts, the temperature was 120 ℃, the liquid flow rate was 5 mL/min, the oxygen pressure was 2.0 MPa, the oxygen flow rate was 14.4 mL/min, the back pressure was 1.5 MPa, and the residence time was 21.4 s. Compared with the traditional batch process, this continuous process improves yield of product with the purity of 99.72% from 85.57% to 95.15%, and production efficiency from 12 g·h–1·L–1 to 3 878 g·h–1·L–1. Furthermore, the high-pressure oxidation process is safer.

  • Caixia CUI, Shicong LI, Wenxing BAO, Zhedong JIN, Yunsheng YUAN
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 184-190.

    The A35R and M1R antigens on the surface of the monkeypox virus(MPXV) play critical roles in mediating viral entry. These two antigens are also important targets for potential vaccine design and therapeutic antibody development. In this study, molecular cloning techniques were employed to construct expression vectors for fusion proteins(A35R-S2 or M1R-S2), which consisted of either A35R or M1R fused with the S2 domain of the Spike(S) protein from severe acute respiratory syndrome(SARS) coronavirus, a domain that mediates membrane fusion between the virus and host cell. These fusion proteins were used to replace the envelope protein component of a lentiviral packaging system. In human embryonic kidney 293T(HEK-293T) cells, a lentiviral vector plasmid inserted a firefly luciferase as reporter gene was packaged into lentiviruses, resulting in engineered lentiviral particles that both display A35R-S2 or M1R-S2 on their envelope and carry the luciferase gene within their genome. In vitro infection assays confirmed that these engineered lentiviruses could effectively infect HEK293T and African green monkey kidney cells(VERO-E6 cells), and that A35R-and M1R-specific antibodies significantly inhibited their infectivities. The results demonstrate that this technical platform, which utilizes monkeypox surface antigen-S2 fusion envelope proteins, can generate monkeypox pseudoviruses that mimic MPXV infection. This system serves as a novel tool for high-throughput screening of therapeutic antibody candidates and preliminary evaluation of vaccine efficacy against monkeypox virus.

  • Wenping WANG, Quancheng CAO, Shaohong YIN, Wenbin ZHOU
    Chinese Journal of Pharmaceuticals. 2026, 57(2): 191-198.

    This study comprehensively evaluated the in vitro pharmaceutical properties and in vivo pharmacokinetic characteristics of sotalol hydrochloride scored tablets(80 mg). The tablets were split along the score line using manual splitting and a mechanical tablet splitter. The mass loss, weight variation, friability, and stability of the split tablets were systematically investigated. The similarity of dissolution profiles between the self-prepared preparations and the reference preparations(the whole and half tablets) was compared in four different dissolution media. A Beagle dog pharmacokinetic model was established to compare key pharmacokinetic parameters between the whole and half tablets. The results showed that both splitting methods achieved uniform tablet division, with mass loss less than 3.0%, weight variation within 85% - 115%, and friability less than 1.0%. After storage at room temperature for 90 d, the split tablets showed no significant changes in appearance, content, impurities, and dissolution compared to the freshly split tablets. The dissolution profiles of the half tablets were similar to those of the whole tablets. Pharmacokinetic data indicated that there was no statistically significant difference in tmax and t1/2 between the half and whole tablets(P>0.05). The AUC for half tablets was approximately 50% of that for whole tablets. This study demonstrated that the test tablets could be split uniformly. The split tablets maintained stable quality, and the half tablets exhibited in vitro dissolution equivalence and a proportional pharmacokinetic relationship with the whole tablets in vivo, supporting the basis for clinical personalized dosing.

News